Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.1% – Time to Buy?

Vor Biopharma Inc. (NASDAQ:VOR) shares were up 6.1% during trading on Tuesday . The stock traded as high as $23.41 and last traded at $23.2250. Approximately 532,604 shares traded hands during trading, a decline of 49% from the average session volume of 1,048,599 shares. The stock had previously closed at $21.89.

Analyst Ratings Changes

Several equities research analysts recently issued reports on VOR shares. Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Wedbush increased their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.38.

Vor Biopharma Price Performance

The stock’s 50 day moving average price is $22.01 and its two-hundred day moving average price is $17.72.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). Research analysts anticipate that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors have recently made changes to their positions in VOR. Bank of America Corp DE grew its holdings in Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after buying an additional 112,496 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Vor Biopharma during the first quarter worth approximately $2,298,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Vor Biopharma during the fourth quarter worth approximately $33,275,000. Wellington Management Group LLP bought a new stake in shares of Vor Biopharma in the second quarter valued at approximately $499,000. Finally, Braidwell LP boosted its position in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after acquiring an additional 106,330 shares during the period. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.